PTGX vs SNY
Protagonist Therapeutics, Inc. vs Sanofi — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
64
Buy
VS
| Metric | PTGX | SNY |
|---|
| AI Score |
64
|
66
|
| Price |
$151.99
|
$43.73
|
| P/E Ratio |
121.74×
|
22.99×
|
| ROE |
-21.2%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
72.8%
|
| Debt / Equity |
0.01×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
68.1
|
53.1
|
| Beta |
1.794
|
0.278
|
| Expected Upside |
—
|
+3.9%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus SNY.
SNY leads by 2 points.
SNY scores 66/100 (Buy) versus PTGX at 64/100 (Buy).
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is price structure making lower highs and lower lows. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 9.6 is inexpensive for the broad market — Value
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.5% pays you to wait — Value
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical